Antidotes in Poisoning : Specific Antidotes
OEXJA1 “Exjade dispersible tablet” 125 mg/tab
適應症：治療因輸血而導致慢性鐵質沈著症（輸血性血鐵質沉積）的成年人及2歲以上兒童患者。
Usual dose:
20mg/kg/day; maintenance, adjust in increments of 5 or 10 mg/kg q3-6mon. based on serum ferritin trends; max. 30 mg/kg/day.
Dose adjustment:
Renal: for increases of serum creatinine of > 33% in adults or > the age-appropriate normal upper limit on 2 consecutive visits, reduce the daily dose by 10 mg/kg.
Hepatic: consider dose modifications or interruption for severe or persistent elevations in transaminase levels.
Adverse effect:
Common: rash, abdominal pain, diarrhea, nausea, vomiting, ALT(SGPT) level raised, headache, proteinuria, serum creatinine raised, cough, nasopharyngitis, fever.
Serious: urticaria, dehydration, agranulocytosis, cytopenia, hemoglobin SS disease with crisis, neutropenia, thrombocytopenia, drug-induced hepatitis, liver failure, anaphylaxis, hypersensitivity disorder, encephalopathy, hearing loss, (acute) renal failure, angioedema.
健保給付規範：(96/7/1、104/12/1)限用於治療因輸血而導致慢性鐵質沉著症（輸血性血鐵質沉積）的成年人及2歲以上兒童患者且符合下列條件之一者：
1.重型海洋性貧血或骨髓造血功能不良症候群、再生不良性貧血患者。
2.需長期輸血治療且已併有鐵質沉積之患者，則在患者血清內鐵蛋白（Ferritin）＞ 2000ug/L時使用。
3.中型(非輸血依賴)海洋性貧血患者：(104/12/1)
(1)使用條件：病患已開始長期接受輸血治療(即一年輸血兩次以上或四個單位以上者)，且血清內鐵蛋白（Ferritin）＞ 800μg/L(至少二次檢查確認，檢查之間隔需經過至少3個月，並排除感染及發炎等狀況)或肝臟鐵質（Liver iron content）> 7mg/g dry weight者。
(2)當肝臟鐵質< 3mg/g dry weight，或血清內鐵蛋白（Ferritin）< 300μg/L時即停藥。